The United Laboratories International Holdings Limited (HK:3933)
:3933
Want to see HK:3933 full AI Analyst Report?
3933 Stock Chart & Stats
HK$11.74
HK$0.26(2.23%)
At close: 4:00 PM EST
HK$11.74
HK$0.26(2.23%)
Day’s Range― - ―
52-Week RangeHK$8.80 - HK$17.98
Previous CloseN/A
Volume6.42M
Average Volume (3M)9.98M
Market Cap
HK$17.52B
Enterprise ValueHK$8.96B
Total Cash (Recent Filing)HK$11.24B
Total Debt (Recent Filing)HK$4.99B
Price to Earnings (P/E)9.4
Beta0.84
Next Earnings
Aug 27, 2026EPS Estimate
0.5Next Dividend Ex-DateN/A
Dividend Yield5.11%
Share Statistics
EPS (TTM)1.14
Shares Outstanding1,973,026,500
10 Day Avg. Volume7,816,257
30 Day Avg. Volume9,977,158
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)1.13
Price to Sales (P/S)1.49
P/FCF Ratio22.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$16.23Price Target Upside38.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)0.69
Revenue Forecast (FY)HK$12.83B
Bulls Say, Bears Say
Bulls Say
Sustainable Gross Margins (~42%)A ~42% gross margin in 2025 indicates durable product-level profitability typical of established pharma manufacturers. Healthy gross margins provide long-term buffer for R&D and manufacturing investment, supporting cash generation and resilience to pricing or cost pressures over multiple quarters.
Conservative Balance Sheet And Low LeverageLow debt-to-equity and steadily growing equity/assets reflect conservative financial structure. This reduces refinancing and solvency risk, preserves strategic optionality for capex or acquisitions, and supports stable operations through industry cycles over the medium term.
Established Product-sales Model With Prior GrowthHistorical revenue expansion from 2020–2023 shows the company has proven commercialization and scale in finished-dosage pharmaceuticals. A product-sales driven model with manufacturing capabilities supports recurring revenue streams and long-term market presence despite near-term volatility.
Bears Say
Recent Revenue Decline (-8.7% In 2025)A meaningful revenue decline in 2025 signals weakening top-line momentum that can persist if driven by competitive loss, product lifecycle issues, or pricing pressure. Sustained revenue weakness would constrain reinvestment, slow scale benefits, and pressure long-term growth prospects.
Weak, Volatile Free Cash Flow ConversionFree cash flow conversion is low and volatile, reducing the reliability of internal funding for dividends, R&D and capex. Even with positive operating cash flow, inconsistent FCF undermines earnings quality and increases reliance on external financing for sustained strategic investments.
Declining Returns On Equity And Margin CompressionA sharp drop in ROE and compressing margins indicate reduced efficiency in converting capital into profits. If persistent, weaker returns make it harder to compete on R&D and commercialization, diminish shareholder returns, and signal potential structural challenges in profitability.
The United Laboratories International Holdings News
3933 FAQ
What was The United Laboratories International Holdings Limited’s price range in the past 12 months?
The United Laboratories International Holdings Limited lowest stock price was HK$8.80 and its highest was HK$17.98 in the past 12 months.
What is The United Laboratories International Holdings Limited’s market cap?
The United Laboratories International Holdings Limited’s market cap is HK$17.52B.
When is The United Laboratories International Holdings Limited’s upcoming earnings report date?
The United Laboratories International Holdings Limited’s upcoming earnings report date is Aug 27, 2026 which is in 98 days.
How were The United Laboratories International Holdings Limited’s earnings last quarter?
The United Laboratories International Holdings Limited released its earnings results on Mar 24, 2026. The company reported HK$0.127 earnings per share for the quarter, beating the consensus estimate of HK$0.069 by HK$0.058.
Is The United Laboratories International Holdings Limited overvalued?
According to Wall Street analysts The United Laboratories International Holdings Limited’s price is currently Undervalued.
Does The United Laboratories International Holdings Limited pay dividends?
The United Laboratories International Holdings Limited pays a Annually dividend of HK$0.175 which represents an annual dividend yield of 5.11%. See more information on The United Laboratories International Holdings Limited dividends here
What is The United Laboratories International Holdings Limited’s EPS estimate?
The United Laboratories International Holdings Limited’s EPS estimate is 0.5.
How many shares outstanding does The United Laboratories International Holdings Limited have?
The United Laboratories International Holdings Limited has 1,973,026,500 shares outstanding.
What happened to The United Laboratories International Holdings Limited’s price movement after its last earnings report?
The United Laboratories International Holdings Limited reported an EPS of HK$0.127 in its last earnings report, beating expectations of HK$0.069. Following the earnings report the stock price went up 2.277%.
Which hedge fund is a major shareholder of The United Laboratories International Holdings Limited?
Currently, no hedge funds are holding shares in HK:3933
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
The United Laboratories International Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$16.23 (38.26% Upside)
HK$16.23 (38.26% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
30.38%
12-Months-Change
Fundamentals
Return on Equity
12.65%
Trailing 12-Months
Asset Growth
24.94%
Trailing 12-Months
Company Description
The United Laboratories International Holdings Limited
The United Laboratories International Holdings Limited (3933) is a Hong Kong-based company primarily engaged in the manufacturing and distribution of pharmaceuticals, including generic and branded drugs. The company operates in various sectors such as healthcare, biotechnology, and consumer products, providing a wide range of pharmaceutical products, including traditional Chinese medicine, over-the-counter medications, and medical devices. United Laboratories focuses on innovation and quality, aiming to meet the growing healthcare demands in both domestic and international markets.
3933 Stock 12 Month Forecast
Average Price Target
HK$16.23
▲(38.26% Upside)
Technical Analysis
China Medical System Holdings
―
Livzon Pharmaceutical Group
―
China Resources Pharmaceutical Group Ltd.
―
Consun Pharmaceutical Group Ltd.
―
Grand Pharmaceutical Group Limited
―
Options Prices
Currently, No data available
---